Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fusidic acid sodium salt (SQ-16360) 是一种Fusidium coccineum 属甾体类抑菌抗生素。它阻止核糖体释放翻译延长因子G 来抑制细菌生长。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
100 mg | ¥ 282 | 现货 | ||
200 mg | ¥ 397 | 现货 | ||
500 mg | ¥ 638 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 150 | 现货 |
产品描述 | Fusidic acid sodium salt (SQ-16360) is a sodium salt form of fusidic acid, a bacteriostatic antibiotic derived from the fungus Fusidium coccineum and used as a topical medication to treat skin infections. |
体内活性 | Fusidin(Fusidate Sodium)至少在一定程度上通过抑制TNF-α的分泌改善EAM[1]。Fusidin显著减轻了给予链脲佐菌素(SZ)的小鼠免疫炎症糖尿病的临床和组织学征象。该作用是剂量依赖性的,且在三个不同的小鼠品系中均有观察到。因此,Fusidin 可能具有抗糖尿病效应[2]。 |
激酶实验 | Binding assays: Binding assays are performed as previously described (Allenby et al., 1993, 1994). Briefly, labeled and unlabeled retinoids are added to nucleosol or cytosolic fractions in ethanol so that the total amount of ethanol added is constant in all tubes and did not exceed 2% of the incubation volume. The receptor preparations are incubated with retinoids at 4°C for 4–6 hr. Sephadex PD-10 desalting columns are used to separate bound radioligand from free radioligand after equilib- rium is achieved. For competitive binding assays, varying concentrations of unlabeled competing ligand are incubated with the appropriate nucleosol or cytosol in the presence of a fixed concentration of [3H]tRA (sp. act. 49.3 Ci/mmol) or [3H]9-cis RA (sp. act. 24.0 Ci/mmol). Final concentrations of [3H] tRA and [3H]9-cis RA for nuclear receptor binding assays are 5 nM. Final concentrations of [3H] tRA for CRABP binding assays is 30 nM. The IC50s are calculated as described above (DeLean et al., 1978). For saturation kinetics, increasing concentrations of radiolabeled ligand ([3H]tRA sp. act. 49.3 Ci/mmol, [3H]TTNPB sp. act. 5.5 Ci/ mmol) are added to the nucleosol of the appropriate receptor subtype in the presence (nonspecific binding) or absence (total binding) of a 100-fold molar excess of the corresponding unlabeled retinoid. Specific binding is defined as the total binding minus nonspecific binding. Saturation kinetics are calculated as previously described (Scatchard, 1949; Grippo and Gudas, 1987; Levin et al., 1992). |
别名 | Sodium fusidate, 夫西地酸钠, Fusidate Sodium, Fucidin, SQ-16360 |
分子量 | 538.69 |
分子式 | C31H47NaO6 |
CAS No. | 751-94-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 93 mg/mL (172.6 mM)
H2O: 92 mg/mL (170.8 mM)
DMSO: 93 mg/mL (172.6 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / H2O / DMSO | 1 mM | 1.8564 mL | 9.2818 mL | 18.5636 mL | 46.4089 mL |
5 mM | 0.3713 mL | 1.8564 mL | 3.7127 mL | 9.2818 mL | |
10 mM | 0.1856 mL | 0.9282 mL | 1.8564 mL | 4.6409 mL | |
20 mM | 0.0928 mL | 0.4641 mL | 0.9282 mL | 2.3204 mL | |
50 mM | 0.0371 mL | 0.1856 mL | 0.3713 mL | 0.9282 mL | |
100 mM | 0.0186 mL | 0.0928 mL | 0.1856 mL | 0.4641 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Fusidic acid sodium salt 751-94-0 Microbiology/Virology Others oxidation-reduction CAT Antibacterial Antibiotic bacteriostatic Sodium fusidate ribosome Fusidic acid Bacterial factor Inhibitor SQ 16360 growth elongation inhibit steroids 夫西地酸钠 Fusidate Sodium Fucidin SQ16360 Fusidic acid sodium SQ-16360 inhibitor